<b>Conclusions</b>: In RA, adiposity-not the tested candidate pharmacogenes-drives NAFLD risk, and <i>SLCO1B1</i>/<i>MTHFR</i> variants do not support MTX dose adjustment. The gene discussed is MTHFR; the disease is metabolic dysfunction-associated steatotic liver disease.